Korean Red Ginseng and Metabolic Syndrome

The Korean Society of Ginseng60 enrolled

Overview

Five factor consisting of Metabolic syndrome is closely linked by insulin resistance. Until now, several studies have been performed about effects of Korea red ginseng on hypertension, diabetes, and hyperlipidemia, but not metabolic syndrome. The investigators hypothesize that Korean red ginseng could improve each constituents of metabolic syndrome, arterial stiffness, and inflammatory markers. The aim of this study is to determine effects of Korean red ginseng on cardiovascular risks in subjects with metabolic syndrome.

The details of study objective are followed by these: * comparison of blood pressure before and after Korean red ginseng administration * comparison of metabolic indicator before and after Korean red ginseng administration * comparison of oxidative stress and inflammatory markers before and after Korean red ginseng administration * comparison of arterial stiffness before and after Korean red ginseng administration

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Metabolic Syndrome

Interventions

Korean red ginsengDIETARY_SUPPLEMENT

5 capsules (300 mg/capsule) three times everyday for 12 weeks

starchDIETARY_SUPPLEMENT

5 capsules three times everyday for 12 weeks

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria:(three or more of following five factors) * waist circumference(male: more than 90cm, female: more than 80cm) * blood pressure(systolic: more than 130mmHg, diastolic: more than 85mmHg) * fasting plasma glucose: more than 100mg/dL * fasting triglycerides: more than 150mg/dL * High-density lipoprotein(HDL)-cholesterol(male: less than 40mg/dL, female: less than 50mg/dL) Exclusion Criteria: (any one of following factors) * uncontrolled blood pressure(systolic: more than 160mmHg, diastolic: more than 100mmHg) or subjects taking blood pressure lowering drug * Type 2 diabetes patients or fasting plasma glucose more than 126mg/dL * triglyceride more than 400mg/dL, total cholesterol more than 250mg/dL * subjects taking antilipidemic drug * past history of coronary heart disease or cerebrovascular disease

Locations (1)

Yonsei Univeristy College of Medicine, Gangnam Severance Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

Change in the Pre- and Post-treatment Systolic Blood Pressure

Time frame: baseline and 12 weeks

Secondary Outcomes

Change in the Pre- and Post-treatment Oxidized Low-densty Lipoprotein(LDL)

Time frame: baseline and 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.